ANNOUNCEMENT NO. 229
15 September 2022
Annual Report 2021/22 (1 July 2021 – 30 June 2022)
Strong growth despite challenging conditions
ChemoMetec grew its revenue by 52% in 2021/22 from DKK 281.1 million to DKK 427.2 million despite the extraordinary market conditions caused by Covid-19 and the war in Ukraine, including supply chain shortages. As a result, EBITDA grew from DKK 135.6 million to DKK 222.9 million, a 64% increase. As in previous years, growth was primarily driven by increasing sales within cell-based therapy, particularly in the North American market.
“In the past year, we have focused intently on coping with various challenges in the wake of Covid-19 and the war in Ukraine – and more generally on navigating ChemoMetec safely through a period in which high growth places great demands on the entire company. These efforts were generally successful, and we are very pleased that our organisation was able to generate this level of growth under difficult circumstances. Going into the new financial year, we have a period ahead of us that will be marked by continuing uncertainty, but we are generally in a good position. We will therefore continue to invest in a sustainable foundation for our business. At the same time, we look forward to launching our new XcytoMatic cell counters, which are expected to contribute significantly to driving the continued growth in the years ahead,” says Steen Søndergaard, CEO.
Financial results
Guidance
Attached to this announcement
The annual report and the extract may also be downloaded from ChemoMetec’s website www.chemometec.com
More information
Steen Søndergaard, CEO, ChemoMetec A/S
Telephone (+45) 48 13 10 20
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.
ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For more information, go to www.chemometec.com.
Attachments
Home Care 100's June gathering served as a critical platform for advancing dialogue around growth,…
NEW YORK, June 13, 2024 /PRNewswire/ -- The healthcare analytics market size in APAC is estimated…
BELLEVUE, Wash.--(BUSINESS WIRE)--$NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today…
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the…
TraceLink Recognized with Top Honor in Supply Chain Visibility at SupplyTech Breakthrough Awards BOSTON, June 13,…
Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern Time PHILADELPHIA,…